Phosphoinositides play key roles in regulating membrane dynamics and intracellular signaling in eukaryotic cells. However, comparable lipid-based signaling pathways have not been identified in bacteria. Here we show that Mycobacterium smegmatis and other Actinomycetes bacteria can synthesize the phosphoinositide, phosphatidylinositol 3-phosphate (PI3P). This lipid was transiently labeled with [3H]inositol. Sensitivity of the purified lipid to alkaline phosphatase, headgroup analysis by high-pressure liquid chromatography, and mass spectrometry demonstrated that it had the structure 1,2-[tuberculostearoyl, octadecenoyl]-sn-glycero 3-phosphoinositol 3-phosphate. Synthesis of PI3P was elevated by salt stress but not by exposure to high concentrations of non-ionic solutes. Synthesis of PI3P in a cell-free system was stimulated by the synthesis of CDP-diacylglycerol, a lipid substrate for phosphatidylinositol (PI) biosynthesis, suggesting that efficient cell-free PI3P synthesis is dependent on de novo PI synthesis. In vitro experiments further indicated that the rapid turnover of this lipid was mediated, at least in part, by a vanadate-sensitive phosphatase. This is the first example of de novo synthesis of PI3P in bacteria, and the transient synthesis in response to environmental stimuli suggests that some bacteria may have evolved similar lipid-mediated signaling pathways to those observed in eukaryotic cells.

Lipids are part of complex signaling networks in eukaryotic cells, controlling numerous biological events. Major membrane lipids such as phosphoinositides, sphingolipids, cholesterol, and glycerophospholipids are all involved in the generation of second messengers. One class of phosphoinositide signaling molecules, phosphatidylinositol 3-phosphate (PI3P), was first identified in mammalian fibroblast cells in 1988 (1) and is now recognized as a ubiquitous and functionally important phosphoinositide that acts as a second messenger mediating various cellular processes such as endocytic membrane trafficking, motility, and cytokine release (2–4). The synthesis of PI3P is mediated by a family of phosphatidylinositol 3-kinases (PI3K), with the class III PI3K Vps34 being present in all eukaryotes examined so far (5), suggesting an ancient origin of phosphoinositide signaling.

In striking contrast, inositol lipid signaling has never been described in bacteria. Bacterial membranes are mainly composed of glycerophospholipids. For example, the plasma membrane of Escherichia coli is composed of three major glycerophospholipids: phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin. Sphingolipids, sterols, and certain glycerophospholipids such as phosphatidylycerine and phosphatidylglycerol (PI) are rarely found in bacteria (6). Interestingly, some bacteria contain phosphoinositide kinases and phosphatases that are capable of producing and hydrolyzing PI3P or PI4-phosphate (PI4P). For example, a protein/lipid kinase purified from Legionella micdadei was shown to phosphorylate PI (7). However, Legionella lacks the capacity to synthesize PI (8), and it is likely that this kinase phosphorylates host PI. A similar modulation of host PI metabolism has been suggested to occur during Salmonella enterica infection by a bacterial phosphoinositide phosphatase SopB (9). In this case, SopB was proposed to dephosphorylate PI3 3,4,5-P3 and PI 3,5-bisphosphate to generate PI3P and modulate host vesicular trafficking. Finally, Rhizobium leguminosarum, a nitrogen-fixing plant symbiont, possesses a phosphotransferase activity that can generate PI4P by transferring phosphate from Lipid A to PI. However, neither the substrate PI nor the product PI4P was detected in the bacterial membrane, leading the authors to suggest that PI4P is the substrate for Lipid A.

The abbreviations used are: PI3P, phosphatidylinositol 3-phosphate; PI4P, phosphatidylinositol 4-phosphate; CDP-DAG, CDP-diacylglycerol; HPLC, high-pressure liquid chromatography; HPTLC, high-performance TLC; LC-MS, mass spectrometry; MS/MS, tandem MS; PI, phosphatidylinositol; PI3K, phosphatidylinositol 3-kinases; PIM, phosphatidylinositol mannoside; GroPIns, glycerophosphoinositol; GroPIns3P, glycerophosphoinositol 3-phosphate; GroPIns4P, glycerophosphoinositol 4-phosphate; ATPyS, adenosine 5’-O-thiotriphosphate; CHES, 2-(cyclohexylamino)ethanesulfonic acid; PIP, phosphatidylinositol monophosphate.

From the Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, and the Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3010, Australia, the Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics, and Victorian Bioinformatics Consortium, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia, and the Research Institute for Microbial Diseases, and WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan

Yasu S. Morita*,‡§1, Yoshiki Yamaryo-Botte¶,‡, Kana Miyanagi*, Judy M. Callaghan*, John H. Patterson*, Paul K. Crellin*, Ross L. Coppol‡, Helen Billman-Jacobs‡, Taroh Kinoshita‡,§4, and Malcolm J. McConville‡4,5

© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

1 Supported by the International Human Frontier Science Program and JSPS (Grant KAKENHI 20590441). To whom correspondence may be addressed: Dept. of Immunoregulation, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan. Tel.: 81-6-6879-8329; Fax: 81-6-6875-5233; E-mail: ymorita@biken.osaka-u.ac.jp.

2 Supported by a National Health and Medical Research Council project grant.

3 Supported by the Knowledge Cluster Initiative of Ministry of Education, Culture, Sports, Science, and Technology, Japan.

4 Both authors contributed equally to this work.

5 A National Health and Medical Research Council Principal Research Fellow and supported by a National Health and Medical Research Council Program Grant. To whom correspondence may be addressed: Dept. of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Royal Parade, Parkville, Victoria 3010, Australia. Tel.: 61-3-8344-5681; Fax: 61-3-9347-7730; E-mail: malcolm@unimelb.edu.au.

6 The abbreviations used are: PI3P, phosphatidylinositol 3-phosphate; PI4P, phosphatidylinositol 4-phosphate; CDP-DAG, CDP-diacylglycerol; HPLC, high-pressure liquid chromatography; HPTLC, high-performance TLC; MS, mass spectrometry; MS/MS, tandem MS; PI, phosphatidylinositol; PI3K, phosphatidylinositol 3-kinases; PIM, phosphatidylinositol mannoside; GroPIns, glycerophosphoinositol; GroPIns3P, glycerophosphoinositol 3-phosphate; GroPIns4P, glycerophosphoinositol 4-phosphate; ATPyS, adenosine 5’-O-thiotriphosphate; CHES, 2-(cyclohexylamino)ethanesulfonic acid; PIP, phosphatidylinositol monophosphate.

Received for publication, March 2, 2010, and in revised form, April 2, 2010. Published, JBC Papers in Press, April 2, 2010, DOI 10.1074/jbc.M110.119263
Phosphatidylinositol 3-Phosphate in Prokaryote

synthesized only during nodulation or that the enzyme utilizes exogenous PI from the host (10). Thus, while some bacteria can express inositol-lipid kinases/phosphotransferases and phosphatases, phosphorylated PI species have not yet been detected in bacteria.

Actinomycetes are a diverse group of Gram-positive bacteria that include important human pathogens such as Mycobacterium tuberculosis and Mycobacterium leprae and the industrially important species, Corynebacterium glutamicum. Unlike most other bacteria, they possess a canonical pathway of de novo PI biosynthesis (11–16), and PI is a major component of the plasma membrane. Furthermore, PI also acts as a membrane anchor for abundant glycolipids, such as PI mannosides (PIMs) and lipoarabinomannan (17). The gene encoding PI synthetase is essential for the growth of Mycobacterium smegmatis, a model organism of mycobacteria, suggesting that PI or its downstream products are essential (18). The abundance of PI and the capacity of mycobacteria to utilize PI for further elaborations led us to ask if these bacteria produce phosphorylated PIs, in a way similar to eukaryotic cells. Here we show that M. smegmatis synthesizes PI3P in response to environmental stimuli. Our study represents the first example of de novo synthesis of PI3P in bacteria and indicates that eukaryote-like lipid-mediated signaling may occur in some bacteria.

EXPERIMENTAL PROCEDURES

Metabolic Labeling—M. smegmatis strain mc²155 (19) was grown at 37 °C in Middlebrook 7H9 broth (Difco), supplemented with 0.2% (w/v) glucose, 0.2% (v/v) glycerol, and 15 mM NaCl. All experiments were performed on cultures harvested at mid-log growth phase. For metabolic labeling, 30 ml of bacterial culture was centrifuged (2,500 × g, 10 min), and the cell pellet was resuspended at 0.25 g/ml in Sauton’s minimal medium prewarmed at 37 °C. After incubation at 37 °C for 15 min, labeling was initiated by addition of [³H]inositol (Amersham Biosciences, 16.0 Ci/mmol, final concentration of 50 μCi/ml) and continued for 5 min. The culture was then chased by dilution in 10 volumes of various solutions (containing 1 mM non-radioactive inositol) as indicated. Aliquots were collected at the indicated time points and snap-frozen in liquid nitrogen prior to analysis. After thawing, bacteria were rapidly centrifuged, and [³H]inositol-labeled lipids were extracted twice in chloroform/methanol (2:1, v/v) and once in chloroform/methanol/water (1:2:0.8, v/v). Dried lipids were suspended in 1-butanol/water (2:1, v/v), and lipids in the upper 1-butanol-rich phase were analyzed by high-performance thin layer chromatography (HPTLC) on aluminum-backed Silica Gel 60 sheets (Merck) developed in chloroform/methanol/ether (10:10:3, v/v). Lipids were further purified by chloroform/methanol/14.6 M ammonia/water (90:70:4:16, v/v, solvent 2). Bovine brain phosphoinositides were visualized by iodine vapor and contours of PI, PI monophosphate (PIP), and PI bisphosphates were marked on the HPTLC plate.

Enzymatic Treatments—Phospholipid species were purified by HPTLC, and silica scrapings were extracted in chloroform/methanol/water (10:10:3, v/v). Lipids were further purified by 1-butanol/water phase partition. Lipids (1000 dpm) were resuspended in 50 mM Tris-HCl (pH 9.0), 1 mM MgCl₂, 0.16% (w/v) sodium deoxycholate (25 μl) and treated with alkaline phosphatase (E. coli C75, Takara, 0.4 unit) at 37 °C for 1 h. Lipids were recovered by 1-butanol/water phase partition and re-analyzed by HPTLC (solvent 1).

Preparation of Yeast and Leishmania Lipid Standards—A strain of Saccharomyces cerevisiae defective in de novo synthesis of inositol (RSY1156) (21) was grown to mid-log growth phase in SC broth, starved for inositol for 2 h, and incubated with [³H]inositol for 6 h. Lipids were extracted as previously described (20). For inositol bisphosphate standards (Fig. 2E), a mixture of inositol 1,3-bisphosphate and inositol 1,4-bisphosphate was prepared from the yeast lipids and mixed with commercially available [³H]inositol 1,4-bisphosphate to give a similar height for both peaks. Leishmania mexicana was metabolically labeled with [³H]inositol, and lipids were extracted as described before (22).

HPLC—HPTLC-purified phospholipids were resuspended in 200 μl of methanol/25% ammonia (1:1, v/v), and incubated at 37 °C overnight. The glycerophosphoinositols (GroPIns) were then recovered by phase partition in 1-butanol/50 mM HEPES (pH 7.4) (2:1, v/v). The lower aqueous phase was dried on a SpeedVac concentrator and analyzed by HPLC (Merck-Hitachi L-6210), using a Partisil 10-SAX-250A column (Alltech) fitted with a guard column. GroPIns was eluted in a stepwise linear gradient of ammonium phosphate (0–5 min, 0 mM; 5–45 min, 0–150 mM; 45–52 min, 150–250 mM; and 52–64 min, 250–1250 mM) at a flow rate of 1 ml/min. For some experiments, GroPIns was further treated for deglyceration using an established protocol (23). Briefly, the glycerol moiety was oxidized in 10 mM periodate (25 °C, 30 min). After quenching excess periodate by 250 mM ethylene glycol (25 °C, 30 min), 0.46% 1-amino-pipерidine was added to eliminate aldehydes (25 °C, 3 h). The sample was purified by passage through a Dowex AG50W column, and the eluate was analyzed by HPLC.

Mass Spectrometry of PI3P—M. smegmatis cell pellets were extracted in chloroform/methanol (2:1, v/v) containing 0.25% HCl. Insoluble material was removed by centrifugation, and the supernatant was partitioned by addition of 1 mM NaCl. The lower organic phase was dried under N₂ and dissolved in chloroform/methanol (10:10:3, v/v). The nebulizer was set at 25 p.s.i. The spray source of a 6410 Triple Quadrupole mass spectrometer (Agilent Technologies). The capillary voltage was set at 4000 V, the gas temperature and flow rate were set to 250 °C and 8 liters/min, respectively. The nebulizer was set at 25 p.s.i. The fragmentor for precursor ion search was set to 80 V and collision energy to 42 eV. Negative ion precursor scanning was performed using m/z 241 and m/z 321 to detect the PI and PIP species, respectively (24). MS/MS experiments were conducted with fragmentor voltages of 80, 90, or 100 V and collision energies of 22, 32, 42, 47, or 50 eV.

Preparation of Cell Membranes—Wild-type M. smegmatis and an inositol auxotroph (ΔinoI) (25) were grown in 7H9
broth, supplemented with 0.2% (w/v) glucose, 0.2% (v/v) glycerol, 15 mM NaCl and, in the case of Δino1, 1 mM inositol and 20 μg/ml kanamycin. *M. smegmatis* Δino1 cells were suspended in the same growth medium without inositol 2 h prior to the preparation of the cell lysates to allow accumulation of CDP-diacylglycerol (CDP-DAG). Cells were harvested by centrifugation, washed in 50 mM HEPES/NaOH (pH 7.4) twice, and suspended in a lysis buffer containing 50 mM HEPES/NaOH (pH 7.4), 15% glycerol, 2 mM EGTA, and Complete Protease Inhibitor Mixture (EDTA-free, Roche Applied Science). Cells were lysed by probe sonication (15 cycles of 30 s with a 30-s interval on ice to keep the lysate cold) at a power setting of 5 (Astrason Ultrasonic Liquid Processor, Misonix, Farmingdale, NY). Unlysed cells and large cell debris were removed by centrifugation (3,000 × g, 10 min × 2), and a cell membrane/cell wall fraction was obtained by ultracentrifugation (257,000 × g, 30 min, 4 °C). The pellet was resuspended in lysis buffer and used for cell-free radiolabeling experiments.

Cell-free Biosynthesis of Phosphorylated PI.—An aliquot of cell membrane suspension was supplemented with 5 mM MgCl₂, 2 mM EGTA, and other components as indicated in each experiment. After 5 min of pre-warming at 37 °C, the reaction was started by the addition of 1.2 μCi of [³H]inositol. The incubation was stopped at 60 min by the addition of chloroform/methanol (1:1, v/v) to achieve a final ratio of chloroform/methanol/water (10:10:3, v/v). Extracted lipids were then subjected to 1-butanol/water phase partition, and purified lipids were fractionated by HPTLC (solvent 1).

RESULTS

*M. smegmatis* was pulse-labeled with [³H]inositol, resulting in the rapid labeling of previously characterized inositol-lipids, including PI, lyso-PI, and the PIM species, AcPIM2 (25). A minor, unidentified species, termed Lipid X, was also labeled in these experiments (Fig. A). The synthesis of this species appeared to be transient, because label was rapidly lost during the chase (Fig. A). Synthesis of Lipid X was also stimulated by changes in extracellular NaCl. *M. smegmatis* was pulse-labeled with [³H]inositol in low salt medium, then chased in the same low salt medium containing excess non-radioactive inositol to deplete labeled Lipid X (Fig. 1B, 30 min). Addition of salt (500 mM NaCl) to these prelabeled cells resulted in a second pulse of Lipid X synthesis within 1 min indicating resynthesis from prelabeled inositol lipids (Fig. 1B). Potassium salts (KCl and KOAc) were even more effective at stimulating Lipid X synthesis, whereas non-ionic solutes such as glycol, glycerol, or sorbitol had no effect on Lipid X synthesis (Fig. 1, A, C, and D). Taken together, these results suggest that Lipid X is rapidly synthesized from pre-existing inositol-lipids and turned over in response to changes in external salt concentrations.

The structure of Lipid X was investigated by HPTLC analysis of the native lipid, and HPLC analysis of the polar headgroup. [³H]Lipid X migrated close to authentic PIP on HPTLC using an oxalic acid-impregnated silica gel plate, that allows clear separation of PI, PIP, and PI bisphosphate species (Fig. 2A). Following treatment with alkaline phosphatase, Lipid X was converted to a faster migrating species with similar HPTLC mobility to PI (Fig. 2B). These analyses suggested that Lipid X is a PI monophosphate. HPLC analysis of the polar headgroup of phosphoinositides is a well established method to determine in which position the inositol ring is phosphorylated (20). Lipid X was treated with mild base to remove fatty acyl groups, and the released GroPIns headgroup was analyzed by anion-exchange HPLC. Two peaks were resolved, containing 89.6% and 10.4% of the radiolabel (Fig. 2C). The retention time of the major peak was similar to that of a PI3P headgroup released from yeast PIPs. To confirm co-elution, we injected the polar headgroups of Lipid X together with the polar headgroups of the yeast PI/PIP standards (Fig. 2D). The Lipid X peaks co-eluted precisely with the yeast GroPIns headgroups as assessed by recovery of radioactivity in each peak. Specifically, the peak correspond-
PHOSPHATIDYLINOSITOL 3-PHOSPHATE IN PROKARYOTE

FIGURE 2. STRUCTURAL CHARACTERIZATION OF LIPID X. A, migration of \(^3\)Hinositol-labeled Lipid X (lane 1) on an oxalic acid-impregnated HPTLC plate in comparison to bovine brain phosphoinositides (lane 2). Contours in lane 2 indicate PI, PIP, and PI bisphosphate (PIP2) from brain phosphoinositides, which were visualized by iodine vapor. B, PI and Lipid X were metabolically labeled with \(^3\)Hinositol, purified by preparative HPTLC, treated with alkaline phosphatase, and resolved by HPTLC. C, \[^3\H]inositol-labeled Lipid X was deacylated, and released GroPIns phosphates were fractionated by HPLC. As an internal standard, GroPIns (generated by deacylating \[^3\H]PI) was co-injected. D, co-elution of mycobacterial Lipid X with the yeast PI3P standard. \[^3\H]inositol-labeled Lipid X was deacylated as in C. \[^3\H]inositol-labeled yeast PI/PiP standards were prepared as described under "Experimental Procedures" and deacylated to produce a mixture of GroPIns, GroPIns3P, and GroPIns4P. The yeast standard mixture containing GroPIns, GroPIns3P, and GroPIns4P (355 cpm) was co-injected into the HPLC column with mycobacterial Lipid X (GroPIns3P/GroPIns4P candidates; 570 cpm/66 cpm). Recovery from the yeast GroPIns peak was 90% (830 cpm). E, inositol polyphosphates were generated by deglyceration of the GroPIns3P peak derived from Lipid X and fractionated by HPLC. Open circles, standards; closed diamonds, deglycerated M. smegmatis PI3P headgroup.

We next determined the precise mass and abundance of mycobacterial PI3P by liquid chromatography-MS. A characteristic ion at \(m/z\) 321 represents the dehydrated diphosphate inositol headgroup derived from PIP. We used this ion and conducted precursor ion scanning of mycobacterial lipid extracts. Strikingly, we detected only a single molecular species of PI at \(m/z\) 957.6. The molecular weight of this species suggested that it contains acyl chains with a combined length of 37 carbons and one double bond (37:1) (Fig. 3A, lower panel). MS/MS analysis of the \(m/z\) 957.6 ion generated characteristic product ions at \(m/z\) 321.1 (IP3, \(m/z\) 321.1), 280.8 (18:1 fatty acid-H), 253.3 (19:0 fatty acid-CO2-H), and 417.2 (lyso phosphatidic acid-H2O-H with 18:1 fatty acid) (Fig. 3B). These analyses suggest that the major molecular species of mycobacterial PI3P carries 19:0 (tuberculostearic) and 18:1 fatty acids.

Addition of a phosphate to the inositol moiety increases the molecular weight of PI by 80 mass units, suggesting that the PI3P species at \(m/z\) 957.6 was derived from a PI species with \(m/z\) ~878. A minor molecular species of PI representing <1% of the total PI pool was detected with this molecular weight (\(m/z\) 877.6 in Fig. 3A, upper panel). We examined the fatty acyl chain composition of each PI species (Fig. 4). A minor peak at...
m/z 823.5 represented a mixture of two PI species, containing either C17:0/C16:0 or C19:0/C14:0 (Fig. 4A). Another minor PI species at m/z 835.6 carried C18:1/C16:0 fatty acids (Fig. 4B), whereas the major molecular species of PI (m/z 851.8) contained C19:0 and C16:0 (Fig. 4C). Finally, the PI species at m/z 877.6 carried C19:0 and C18:1 acyl chains (Fig. 4D), being consistent with the fatty acid composition of PI3P. This minor PI species may represent a precursor and/or product of PI3P synthesis and turnover (see “Discussion”).

We next estimated the quantity of PI3P in mycobacterial lipid extracts by liquid chromatography-MS multiple reaction monitoring with an internal standard (Fig. 5). We used a synthetic amino-PI3P (m/z 848.2) as an internal standard and confirmed the production of the characteristic dehydrated diphosphate inositol ion at m/z 321 (Fig. 5A). We then analyzed a fixed concentration of mycobacterial PI3P spiked with increasing concentrations of amino-PI3P (Fig. 5B). Responses increased linearly with the increasing concentrations of amino-PI3P. Using this standard curve, mycobacterial PI3P (based on a fixed concentration) was estimated to be present at a concentration of 2.3 g/g wet cell pellet under standard growth condition, corresponding to 8.100^11 PI3P molecules per cell or 1.6% of total PI in the plasma membrane.

To examine the enzymatic characteristics of PI3P synthesis, we developed a cell-free system for mycobacterial PI3P biosynthesis. Incubation of the membrane fraction with [3H]PI and phosphate donors under various conditions did not produce PI3P (data not shown). Given the unusual lipid composition of mycobacterial PI3P, we examined whether endogenous PI might be a better substrate for the putative PI3P synthase. The mycobacterial membrane fraction was incubated with [3H]inositol and various nucleotides. Supplementation
**Phosphatidylinositol 3-Phosphate in Prokaryote**

**FIGURE 6. Synthesis of PI3P in a mycobacterial cell-free system.** A, the membrane fraction from a wild-type strain was incubated with \[^{3}H\]inositol and various nucleotides (2 mM). Ins, inositol. B, PI3P was synthesized in a cell-free system, and a crude lipid extract was treated with 11 units of alkaline phosphatase from bovine intestinal mucosa (Sigma-Aldrich) in a buffer containing 1 mM CHES (pH 9.8), 1 mM MgCl\(_2\), and 0.008% Triton X-100 at 37 °C for 2 h. Lipid extracts from \[^{3}H\]inositol-labeled \(L\). *mexicana* was used as a control, showing that alkaline phosphatase digested PIP specifically without digesting glycoinositol phospholipids (iM2, iM3, and iM4) (22). C, PI3P was prepared by incubating wild-type membranes with \[^{3}H\]inositol and CTP. Crude lipid extracts were deacylated and applied to an HPLC. Detection of GroPIns3P by incubating wild-type membranes with \[^{3}H\]inositol and CTP. Crude lipid extracts were deacylated and analyzed by HPLC. A, the membrane fraction from a wild-type strain was incubated with \[^{3}H\]inositol and various nucleotides (2 mM). E, reactions were performed as in D with various concentrations of nucleoside triphosphates (NTPs), and plotted as relative radioactivities. Filled symbols, CTP; open symbols, ATP; squares, PI; circles, PI3P. Averages of triplicates with standard deviations are shown. F, the effect of sodium orthovanadate was examined using the system as in D. No nucleotide was added. Averages of triplicates with standard deviations are shown. Open circle, PI; closed square, PI3P.

with CTP, but not ATP, resulted in robust synthesis of both PI and PI3P (Fig. 6A). PI3P synthesized in this cell-free system was sensitive to alkaline phosphatase (Fig. 6B). To determine if the phosphate is linked to 3-OH of inositol residue, the crude lipid extract was deacylated and subjected to HPLC analysis. As shown in Fig. 6C, we identified a peak corresponding to GroPIns3P in addition to GroPIns derived from PI. These data suggest that PI3P synthesis was reconstituted in a cell-free system. The requirement for CTP may reflect the need for this nucleotide in the synthesis of CDP-DAG, the lipid acceptor for PI synthetase, or as the donor substrate for PI3K. To distinguish between these two possibilities, we took advantage of an *M. smegmatis* \(\Delta ino1\) mutant that is auxotrophic for inositol (25) and prepared membranes after inositol starvation. Using this \(\Delta ino1\) cell-free system, synthesis of PI was reconstituted by the addition of \[^{3}H\]inositol alone, without added NTPs (Fig. 6D), suggesting that CDP-DAG accumulated during starvation. Significantly, PI3P was also synthesized under these conditions, suggesting that the phosphate donor for PI3P synthesis was endogenously available and the requirement for exogenous CTP in the wild-type membrane system was primarily to allow synthesis of CDP-DAG. Addition of CTP, ATP, and to a lesser extent GTP, enhanced PI and PI3P synthesis by the \(\Delta ino1\) membranes. CTP was the most efficient substrate to produce PI, being consistent with its role in generating CDP-DAG. Addition of CTP and ATP together did not show synergistic effects on PI3P synthesis (Fig. 6D, compare lanes 3 and 5), suggesting that CTP was sufficient for PI3P synthesis as well. Adding increasing concentrations of CTP to the \(\Delta ino1\) membranes stimulated PI synthesis, with concomitant increase in PI3P synthesis, although the stimulatory effect on PI3P synthesis started to plateau at 1 mM (Fig. 6E). Addition of ATP also stimulated PI and PI3P synthesis, but to a lesser extent, and concentrations above 0.5 mM had no effect on the synthesis of either phospholipid (Fig. 6E). These results suggest that PI3P synthesis is more efficient when it is coupled to relatively lower rates of \(de novo\) PI synthesis. When PI synthesis rates become high, PI3P synthesis starts to plateau. Although both CTP and ATP stimulate PI and PI3P synthesis, the precise phosphate donor for the PI3P synthesis remains undefined.

Because metabolic labeling experiments showed only transient accumulation of PI3P, it appeared reasonable to speculate that PI3P levels are controlled by the balance of a synthase/kinase and a phosphatase. We tested if kinase inhibitors can inhibit mycobacterial PI3P synthesis. Wortmannin and LY294002, two well known inhibitors of PI kinases, showed no effect on mycobacterial PI3P synthesis in the cell-free system (data not shown). Similarly, cell-free PI3P synthesis was unaffected by staurosporine, a more general kinase inhibitor, and ATPyS, a non-hydrolyzable ATP analog (data not shown). In contrast, addition of sodium orthovanadate, a potent phosphatase inhibitor, to the cell-free system resulted in increased PI3P labeling (Fig. 6F), suggesting that PI3P levels are controlled in part by a catabolic pathway.

Finally, we wanted to examine if PIP synthesis is conserved in other bacteria. Corynebacteria are a group of bacteria that include medically and industrially important bacteria. They belong to the order Actinomycetales and are evolutionary related to mycobacteria. We radiolabeled *C. glutamicum* with \[^{3}H\]inositol and analyzed extracted lipids by HPTLC. We identified a lipid species with the same HPTLC mobility as mycobacterial PI3P (Fig. 7A). It was sensitive to alkaline phosphatase treatment, and the dephosphorylated product migrated with the same \(R\) value as PI (Fig. 7B). These data indicate that corynebacteria produce a PIP species. When radiolabeled species were chased in phosphate-buffered saline, the PIP species decreased in quantity while the level of radiolabeled PI remained unchanged (Fig. 7A). These data together
metabolism (29). To gain further insights into mycobacterial PI3P metabolism, we reconstituted PI3P synthesis and catabolism in a cell-free system. Our analyses suggested that PI3P is synthesized by an unusual kinase or phosphotransferase system and is catabolized by a vanadate-sensitive phosphatase. Inhibitors of eukaryotic PI kinases, such as Wortmannin and LY294002, showed no effects on mycobacterial PI3P synthesis. Although Wortmannin-insensitive kinases involved in PI3P synthesis have been described in various eukaryotic cells (30–32), these observations are also consistent with the existence of a novel phosphorylation mechanism for the synthesis of mycobacterial PI3P. Because we could not uncouple PI and PI3P synthesis in our cell-free system, it is currently difficult to pinpoint the phosphate donor for PI3P synthesis. Further studies are required to characterize the enzymatic mechanisms of PI3P synthesis, and more importantly identify the enzymes involved in PI3P metabolism.

Fatty acid composition of mycobacterial PI3P appeared to be homogeneous, carrying C19:0/C18:1 fatty acids. The 19:0 fatty acid is likely to be a 10-methylstearic acid, known as tuberculostearic acid, which is a characteristic fatty acyl moiety of mycobacterial phospholipids (33, 34). Interestingly, the fatty acid composition of PI3P was different from the major PI species, carrying C19:0/C16:0. These analyses suggest that the enzyme responsible for synthesis of PI3P only utilizes a minor pool of PI, or that PI3P synthesized from bulk PI undergoes fatty acid remodeling. It is noteworthy that PIM species, a class of glycosylated PIs, predominantly carry C19:0/C16:0 fatty acids (35, 36), apparently utilizing the bulk PI for their synthesis. Therefore, the unusual fatty acid composition of PI3P is a novel and unique aspect of mycobacterial PI metabolism. PI species with distinctive fatty acid compositions appear to be utilized for PIP synthesis in mammalian and yeast cells (37, 38). It remains unknown why and how phosphoinositides with distinct fatty acid compositions are produced, but it is interesting that some features are shared between the eukaryotic and mycobacterial PI3P metabolic pathways. Taken together, it is tempting to speculate that the functions of mycobacterial PI3P are evolutionary related to those of eukaryotic counterparts.

**Phosphatidylinositol 3-Phosphate in Prokaryote**

PI3P metabolism, we reconstituted PI3P synthesis and catabolism in a cell-free system. Our analyses suggested that PI3P is synthesized by an unusual kinase or phosphotransferase system and is catabolized by a vanadate-sensitive phosphatase. Inhibitors of eukaryotic PI kinases, such as Wortmannin and LY294002, showed no effects on mycobacterial PI3P synthesis. Although Wortmannin-insensitive kinases involved in PI3P synthesis have been described in various eukaryotic cells (30–32), these observations are also consistent with the existence of a novel phosphorylation mechanism for the synthesis of mycobacterial PI3P. Because we could not uncouple PI and PI3P synthesis in our cell-free system, it is currently difficult to pinpoint the phosphate donor for PI3P synthesis. Further studies are required to characterize the enzymatic mechanisms of PI3P synthesis, and more importantly identify the enzymes involved in PI3P metabolism.

Fatty acid composition of mycobacterial PI3P appeared to be homogeneous, carrying C19:0/C18:1 fatty acids. The 19:0 fatty acid is likely to be a 10-methylstearic acid, known as tuberculostearic acid, which is a characteristic fatty acyl moiety of mycobacterial phospholipids (33, 34). Interestingly, the fatty acid composition of PI3P was different from the major PI species, carrying C19:0/C16:0. These analyses suggest that the enzyme responsible for synthesis of PI3P only utilizes a minor pool of PI, or that PI3P synthesized from bulk PI undergoes fatty acid remodeling. It is noteworthy that PIM species, a class of glycosylated PIs, predominantly carry C19:0/C16:0 fatty acids (35, 36), apparently utilizing the bulk PI for their synthesis. Therefore, the unusual fatty acid composition of PI3P is a novel and unique aspect of mycobacterial PI metabolism. PI species with distinctive fatty acid compositions appear to be utilized for PIP synthesis in mammalian and yeast cells (37, 38). It remains unknown why and how phosphoinositides with distinct fatty acid compositions are produced, but it is interesting that some features are shared between the eukaryotic and mycobacterial PI3P metabolic pathways. Taken together, it is tempting to speculate that the functions of mycobacterial PI3P are evolutionary related to those of eukaryotic counterparts.

**REFERENCES**

1. Whitman, M., Downes, C. P., Keeler, M., Keller, T., and Cantley, L. (1988) Nature 332, 644–646
2. Kutateladze, T. G. (2006) Biochim. Biophys. Acta 1761, 868–877
3. Falasca, M., and Maffucci, T. (2006) Arch. Physiol. Biochem. 112, 274–284
4. Lindmo, K., and Stenmark, H. (2006) J. Cell Sci. 119, 605–614
5. Engelman, J. A., Luo, J., and Cantley, L. C. (2006) Nat. Rev. Genet. 7, 606–619
6. Geiger, O., González-Silva, N., Lúpez-Lara, I. M., and Sohlenkamp, C. (2010) Prog Lipid Res. 49, 46–60
7. Saha, A. K., Dowling, J. N., Mukhopadhyay, N. K., and Glew, R. H. (1989) J. Bacteriol. 171, 5103–5110

**Acknowledgments**—We thank Keiko Kinoshita (Osaka University) for assistance, Dr. Thasitha Rupasinghe (Metabolomics Australia, Bio21 Institute, Melbourne) for mass spectrometry analysis, Dr. Leon Helfenbaum (University of Melbourne) for provision of yeast inositol auxotroph strains, and Prof. Andrew Holmes (University of Melbourne, Bio21 Institute) for providing synthetic amino-PI3P.
Phosphatidylinositol 3-Phosphate in Prokaryote

8. Finnerty, W. R., Makula, R. A., and Feeley, J. C. (1979) Ann. Intern Med. 90, 631–634
9. Hernandez, L. D., Hueffer, K., Wenk, M. R., and Galán, J. E. (2004) Science 304, 1805–1807
10. Basu, S. S., York, J. D., and Raetz, C. R. (1999) J. Biol. Chem. 274, 11139–11149
11. Ventura, M., Canchaya, C., Tauch, A., Chandra, G., Fitzgerald, G. F., Chater, K. F., and van Sinderen, D. (2007) Microbiol. Mol. Biol. Rev. 71, 495–548
12. Brennan, P. J., and Lehane, D. P. (1971) Lipids 6, 401–409
13. Yano, I., Furukawa, Y., and Kusunose, M. (1969) J. Bacteriol. 98, 124–130
14. Tabaud, H., Tisnovska, H., and Vilkas, E. (1971) Biochimie 53, 55–61
15. Kataoka, T., and Nojima, S. (1967) Biochim. Biophys. Acta 144, 681–683
16. Brennan, P., and Ballou, C. E. (1968) Biochem. Biophys. Res. Commun. 30, 69–75
17. Brennan, P. J. (2003) Tuberculosis 83, 91–97
18. Jackson, M., Crick, D. C., and Brennan, P. J. (2000) J. Biol. Chem. 275, 30092–30099
19. Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., and Jacobs, W. R., Jr. (1990) Mol. Microbiol. 4, 1911–1919
20. Dove, S. K., and Michell, R. H. (1999) in Signal Transduction: A Practical Approach (Milligan, G., ed) 2nd Ed., pp. 255–280, Oxford University Press, Oxford
21. Doering, T. L., and Schekman, R. (1996) EMBO J. 15, 182–191
22. Dalton, J. E., and McConville, M. J. (1998) J. Biol. Chem. 273, 4245–4257
23. Brearley, C. A., and Hanke, D. E. (1997) in Signalling by Inositides: A Practical Approach (Shears, S., ed) pp. 1–32, IRL Press at Oxford University Press, Oxford
24. Hsu, F. F., and Turk, J. (2000) J. Am. Soc. Mass Spectrom 11, 986–999
25. Haites, R. E., Morita, Y. S., McConville, M. J., and Billman-Jacobe, H. (2005) J. Biol. Chem. 280, 10981–10987
26. Romantsov, T., Guan, Z., and Wood, J. M. (2009) Biochim. Biophys. Acta 1788, 2092–2100
27. Irarrazabal, C. E., Burg, M. B., Ward, S. G., and Ferraris, J. D. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 8882–8887
28. Leshem, Y., Seri, L., and Levine, A. (2007) Plant J. 51, 185–197
29. Hatzios, S. K., Iavarone, A. T., and Bertozzi, C. R. (2008) Biochemistry 47, 5823–5831
30. Cameroti, E., De Virgilio, C., and Deloche, O. (2006) J. Biol. Chem. 281, 38139–38149
31. Lemke, L. E., Paine-Murrieta, G. D., Taylor, C. W., and Powis, G. (1999) Cancer Chemother. Pharmacol. 44, 491–497
32. Lyman, J. S., Gallagher, K. L., Clunn, G. F., Fexby, S. E., Patel, M. K., and Hughes, A. D. (2003) FEBS Lett. 555, 591–596
33. Lennarz, W. J., Scheuerbrandt, G., and Bloch, K. (1962) J. Biol. Chem. 237, 664–671
34. Spielman, M. A. (1934) J. Biol. Chem. 106, 87–96
35. Morita, Y. S., Patterson, J. H., Billman-Jacobe, H., and McConville, M. J. (2004) Biochem. J. 378, 589–597
36. Kordulakova, J., Gilleron, M., Mikusova, K., Puzo, G., Brennan, P. J., Gicquel, B., and Jackson, M. (2002) J. Biol. Chem. 277, 31335–31344
37. Wenk, M. R., Lucast, L., Di Paolo, G., Romanelli, A. J., Suchy, S. F., Nussbaum, R. L., Cline, G. W., Shulman, G. I., McMurray, W., and De Camilli, P. (2003) Nat. Biotechnol. 21, 813–817
38. Milne, S. B., Ivanova, P. T., DeCamp, D., Hsueh, R. C., and Brown, H. A. (2005) J. Lipid Res. 46, 1796–1802